Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Oncogene
|
August 9, 2001
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications
T Hideshima, D Chauhan, R Schlossman, et al.
Journal of Virology
|
May 1, 1984
Localization of the simian virus 40 small t antigen in the nucleus and cytoplasm of monkey and mouse cells
M Ellman, I Bikel, J Figge, et al.
Annals of Internal Medicine
|
June 1, 1980
Aplastic anemia and sulindac
L Bennett, R Schlossman, J Rosenthal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 8, 2001
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
S P Treon, C Mitsiades, N Mitsiades, et al.
Blood
|
July 27, 2001
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
C S Mitsiades, S P Treon, N Mitsiades, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 5, 2000
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
E Orsini, E P Alyea, A Chillemi, et al.
Leukemia & Lymphoma
|
March 1, 1995
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma
M V Seiden, R Schlossman, J Andersen, et al.
Bone Marrow Transplantation
|
March 29, 2000
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion
E Orsini, E P Alyea, R Schlossman, et al.
Blood
|
June 20, 1998
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
E P Alyea, R J Soiffer, C Canning, et al.
Oncogene
|
October 4, 2006
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D Chauhan, M Velankar, M Brahmandam, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Oncogene
|
August 9, 2001
The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications
T Hideshima, D Chauhan, R Schlossman, et al.
Journal of Virology
|
May 1, 1984
Localization of the simian virus 40 small t antigen in the nucleus and cytoplasm of monkey and mouse cells
M Ellman, I Bikel, J Figge, et al.
Annals of Internal Medicine
|
June 1, 1980
Aplastic anemia and sulindac
L Bennett, R Schlossman, J Rosenthal, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
June 8, 2001
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
S P Treon, C Mitsiades, N Mitsiades, et al.
Blood
|
July 27, 2001
TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications
C S Mitsiades, S P Treon, N Mitsiades, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
August 5, 2000
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
E Orsini, E P Alyea, A Chillemi, et al.
Leukemia & Lymphoma
|
March 1, 1995
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma
M V Seiden, R Schlossman, J Andersen, et al.
Bone Marrow Transplantation
|
March 29, 2000
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion
E Orsini, E P Alyea, R Schlossman, et al.
Blood
|
June 20, 1998
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
E P Alyea, R J Soiffer, C Canning, et al.
Oncogene
|
October 4, 2006
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma
D Chauhan, M Velankar, M Brahmandam, et al.
Page
of 3